29 April 2021
Ya Ma, a senior associate in the Beijing office of Freshfield Bruckhaus Deringer, is one of 31 lawyers the firm has appointed counsel. The lawyers represent the firm’s most senior lawyers who are not partners.
Ma’s practice is focused on cross-border M&A transactions, foreign direct investments in China and other general corporate and commercial matters with a focus on the life sciences sector. Her practice also includes China-related regulatory matters in the life sciences industry. She has extensive experience advising pharmaceutical, medical device, healthcare, food and cosmetics companies on issues including clinical trials, marketing authorizations, GxP compliance, ADE/AE reporting and marketing and promotional activities.
Her recent work includes advising Roche on its (i) commercial and related pharmaceutical regulatory advice in relation to an arrangement for product development, clinical trials and eventual commercialization of a pipeline Roche product in China; and (ii) regulatory and contractual advice in relation to setting up toll-manufacturing of a new product and transfer of pharmaceutical product registrations in China, and advising Starbucks on the US$1.3 billion buy-out of its East China joint venture from its long-term joint venture partners Uni-President Enterprises Corporation and President Chain Store Corporation. The deal marks the biggest acquisition in the history of Starbucks.
Please wait while the page is loading...
